JP5441287B2 - 心血管事象を予防するための必須脂肪酸 - Google Patents
心血管事象を予防するための必須脂肪酸 Download PDFInfo
- Publication number
- JP5441287B2 JP5441287B2 JP2000599384A JP2000599384A JP5441287B2 JP 5441287 B2 JP5441287 B2 JP 5441287B2 JP 2000599384 A JP2000599384 A JP 2000599384A JP 2000599384 A JP2000599384 A JP 2000599384A JP 5441287 B2 JP5441287 B2 JP 5441287B2
- Authority
- JP
- Japan
- Prior art keywords
- dha
- epa
- ethyl ester
- fatty acids
- essential fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本発明による治療の有効性は例えば、実質的に以下のごとく設計されたプロトコルを3.5年間継続した臨床試験で、梗塞後死亡率がこのような治療によって予想以上の極めて有意な減少を示したという事実によって証明される:
1 “対照”グループ1は、梗塞患者に常用の標準療法で治療した;
2 “処理”グループ2は、“対照”グループに与えた療法に加えて、85%のEPA+DHA(1g/日)を投与した;
3 “処理”グループ3は、“対照”グループに与えた療法に加えて、ビタミンEを投与した;
4 “処理”グループ4は、“対照”グループに与えた療法に加えて、ビタミンEと85%のEPA+DHA(1g/日)とを投与した。
以下の組成を有しており1カプセルあたり1gの有効成分(EPA+DHA、85%力価)を含有するカプセルを公知の製薬技術に従って調製する。
EPA−エチルエステル 525mg/カプセル
DHA−エチルエステル 315mg/カプセル
d−アルファトコフェロール 4IU/カプセル
ゼラチン 246mg/カプセル
グリセロール 118mg/カプセル
赤色酸化鉄 2.27mg/カプセル
黄色酸化鉄 1.27mg/カプセル
ポリ不飽和脂肪酸のエチルエステル 1000mg
エチルエステル中の
ω−3ポリ不飽和エステル
(エイコサペンタエン酸(EPA)、
ドコサヘキサエン酸(DHA))の含量 850mg
d−1−α トコフェロール 0.3mg
ゼラチンスクシネート 233mg
グリセロール 67mg
p−オキシ安息香酸ナトリウム 1.09mg
プロピルp−オキソ安息香酸ナトリウム 0.54mg
Claims (4)
- エイコサペンタエン酸エチルエステル(EPA)とドコサヘキサエン酸エチルエステル(DHA)とを含有する必須脂肪酸混合物を含み、前記混合物中のEPA+DHAの含量が約84%−約100重量%であり、心筋梗塞の病歴のある患者の突然死による死亡率を約40%低下させるための経口投与用医薬組成物。
- 前記混合物中のEPA+DHAの含量が約85重量%であることを特徴とする請求項1に記載の医薬組成物。
- 約0.7g−約1.5g/日の用量で経口投与されることを特徴とする請求項1又は2に記載の医薬組成物。
- EPA+DHA混合物のEPA/DHA比が約0.9−約1.5であることを特徴とする請求項1乃至3のいずれか1項に記載の医薬組成物。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT1999MI000313A IT1308613B1 (it) | 1999-02-17 | 1999-02-17 | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
IT99A000313 | 1999-02-17 | ||
ITMI99A000313 | 1999-02-17 | ||
PCT/EP2000/000957 WO2000048592A1 (en) | 1999-02-17 | 2000-02-07 | Essential fatty acids in the prevention of cardiovascular events |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010014742A Division JP2010116414A (ja) | 1999-02-17 | 2010-01-07 | 心血管事象を予防するための必須脂肪酸 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002537252A JP2002537252A (ja) | 2002-11-05 |
JP5441287B2 true JP5441287B2 (ja) | 2014-03-12 |
Family
ID=11381919
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000599384A Expired - Lifetime JP5441287B2 (ja) | 1999-02-17 | 2000-02-07 | 心血管事象を予防するための必須脂肪酸 |
JP2010014742A Pending JP2010116414A (ja) | 1999-02-17 | 2010-01-07 | 心血管事象を予防するための必須脂肪酸 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010014742A Pending JP2010116414A (ja) | 1999-02-17 | 2010-01-07 | 心血管事象を予防するための必須脂肪酸 |
Country Status (26)
Country | Link |
---|---|
US (2) | US7462643B1 (ja) |
EP (2) | EP1247523A1 (ja) |
JP (2) | JP5441287B2 (ja) |
KR (2) | KR100823051B1 (ja) |
CN (1) | CN1230159C (ja) |
AT (1) | ATE216230T1 (ja) |
AU (1) | AU775078B2 (ja) |
BR (1) | BR0008153A (ja) |
CA (1) | CA2362271C (ja) |
CZ (1) | CZ301307B6 (ja) |
DE (1) | DE60000133C5 (ja) |
DK (1) | DK1152755T3 (ja) |
EA (1) | EA004312B1 (ja) |
ES (1) | ES2174814T3 (ja) |
HK (1) | HK1044720B (ja) |
HU (1) | HUP0200111A3 (ja) |
ID (1) | ID30205A (ja) |
IL (2) | IL144377A0 (ja) |
IT (1) | IT1308613B1 (ja) |
NO (1) | NO328797B1 (ja) |
NZ (1) | NZ513093A (ja) |
PL (1) | PL209078B1 (ja) |
PT (1) | PT1152755E (ja) |
SK (1) | SK286523B6 (ja) |
WO (1) | WO2000048592A1 (ja) |
ZA (1) | ZA200106029B (ja) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1308613B1 (it) * | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
ITMI20010129A1 (it) * | 2001-01-25 | 2002-07-25 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella terapia di insufficienza cardiaca e scompenso cardiaco |
ITMI20012384A1 (it) * | 2001-11-12 | 2003-05-12 | Quatex Nv | Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori |
ITMI20020269A1 (it) * | 2002-02-12 | 2003-08-12 | Victorix Assets Ltd | Uso di steri etilici di acidi poliinsaturi omega-3 in pazienti con insufficienza cardiaca |
GB0210212D0 (en) * | 2002-05-03 | 2002-06-12 | Univ Southampton | Effects of dietary N-3 and N-6 pufa intake on atheromatous plaque stability |
US8729124B2 (en) | 2002-03-05 | 2014-05-20 | Pronova Biopharma Norge As | Use of EPA and DHA in secondary prevention |
EP1501493B1 (en) | 2002-05-03 | 2009-10-07 | Pronova BioPharma Norge AS | Use of epa and dha in secondary prevention of strokes |
ITMI20022511A1 (it) * | 2002-11-26 | 2004-05-27 | Victorix Assets Ltd | Uso di composizioni farmaceutiche contenenti esteri etilici di acidi poliinsaturi omega-3 nella orevenzione della fibrillazione atriale. |
DE602005026582D1 (de) | 2005-03-11 | 2011-04-07 | Recon Oil Ind Private Ltd | Synergistisch hitzestabiles ölmedium mit eicosapentaensäure (epa) und docosahexaensäure (dha) |
JP5134916B2 (ja) * | 2005-07-08 | 2013-01-30 | 持田製薬株式会社 | 心血管イベント発症予防用組成物 |
KR101465717B1 (ko) * | 2005-07-08 | 2014-12-01 | 모치다 세이야쿠 가부시키가이샤 | 심혈관 이벤트 발병 예방용 조성물 |
PL1962825T3 (pl) * | 2005-12-21 | 2014-09-30 | Brudy Tech S L | Zastosowanie DHA do leczenia patologii związanej z oksydacyjnym uszkodzeniem komórkowym |
ES2277557B1 (es) * | 2005-12-21 | 2008-07-01 | Proyecto Empresarial Brudy, S.L. | Utilizacion de acido docosahexaenoico para el tratamiento del daño celular oxidativo. |
EP2526937A1 (en) | 2006-02-07 | 2012-11-28 | Mochida Pharmaceutical Co., Ltd. | Composition for prevention of recurrence of stroke |
EP2777701A1 (en) | 2006-05-31 | 2014-09-17 | Mochida Pharmaceutical Co., Ltd. | Composition for preventing the occurrence of a cardiovascular event in multiple risk patient comprising the ethyl ester of all-cis-5,8,11,14,17-icosapentaenoic acid |
US20090264520A1 (en) * | 2008-04-21 | 2009-10-22 | Asha Lipid Sciences, Inc. | Lipid-containing compositions and methods of use thereof |
US8592439B2 (en) | 2008-08-07 | 2013-11-26 | Spa Societa Prodotti Antibiotici S.P.A. | Long-term treatment of symptomatic heart failure |
WO2010018856A1 (ja) * | 2008-08-13 | 2010-02-18 | 持田製薬株式会社 | カンナビノイド受容体関連疾患の予防/改善または治療剤 |
US20110144667A1 (en) * | 2009-09-08 | 2011-06-16 | Anthony Richard Horton | Hernia patch |
CN104974030A (zh) | 2009-12-30 | 2015-10-14 | 巴斯夫制药(卡兰尼什)公司 | 用于纯化多不饱和脂肪酸的模拟移动床色谱分离方法 |
US8952000B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events |
US9119826B2 (en) | 2011-02-16 | 2015-09-01 | Pivotal Therapeutics, Inc. | Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels |
US8951514B2 (en) | 2011-02-16 | 2015-02-10 | Pivotal Therapeutics Inc. | Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels |
US8715648B2 (en) | 2011-02-16 | 2014-05-06 | Pivotal Therapeutics Inc. | Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics |
GB201111601D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New process |
GB201111594D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New improved process |
GB201111595D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Improved process |
GB201111591D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | Further new process |
GB201111589D0 (en) | 2011-07-06 | 2011-08-24 | Equateq Ltd | New modified process |
KR101681907B1 (ko) * | 2012-02-27 | 2016-12-12 | 주식회사 케어사이드 | 혈액 순환 촉진 및 피부 질환 개선용 조성물 |
US20160228397A1 (en) | 2012-03-30 | 2016-08-11 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions |
CN109966279A (zh) | 2012-03-30 | 2019-07-05 | 微团生物制药有限公司 | ω-3脂肪酸酯组合物 |
US10898458B2 (en) | 2012-03-30 | 2021-01-26 | Micelle Biopharma, Inc. | Self-micellizing fatty acids and fatty acid ester compositions and their use in the treatment of disease states |
US9480651B2 (en) | 2012-03-30 | 2016-11-01 | Sancilio & Company, Inc. | Omega-3 fatty acid ester compositions unitary pharmaceutical dosage forms |
EP2897595B1 (en) * | 2012-09-24 | 2020-06-03 | Aker Biomarine Antarctic As | Omega -3 compositions |
GB201300354D0 (en) | 2013-01-09 | 2013-02-20 | Basf Pharma Callanish Ltd | Multi-step separation process |
US8802880B1 (en) | 2013-05-07 | 2014-08-12 | Group Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
US9428711B2 (en) | 2013-05-07 | 2016-08-30 | Groupe Novasep | Chromatographic process for the production of highly purified polyunsaturated fatty acids |
EP2883860B1 (fr) | 2013-12-11 | 2016-08-24 | Novasep Process | Procédé chromatographique de production d'acides gras polyinsaturés |
JP6303017B2 (ja) | 2014-01-07 | 2018-03-28 | ノヴァセプ プロセスNovasep Process | 芳香族アミノ酸を精製する方法 |
PL237374B1 (pl) * | 2017-11-10 | 2021-04-06 | Lambdafin Spolka Z Ograniczona Odpowiedzialnoscia | Kompozycja farmaceutyczna zawierająca mieszaninę estru etylowego kwasu eikozapentaenowego i estru etylowego kwasu dokozaheksaenowego oraz jej zastosowanie |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6034156A (ja) * | 1983-08-08 | 1985-02-21 | Hayashibara Biochem Lab Inc | エイコサペンタエン酸包接化合物及びこれを含有した飲食物 |
US4526902A (en) * | 1983-10-24 | 1985-07-02 | Century Laboratories, Inc. | Combined fatty acid composition for treatment or prophylaxis of thrombo-embolic conditions |
NO157302C (no) | 1985-12-19 | 1988-02-24 | Norsk Hydro As | Fremgangsmaate for fremstilling av et fiskeoljekonsentrat. |
US4920098A (en) | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
IT1205043B (it) | 1987-05-28 | 1989-03-10 | Innova Di Ridolfi Flora & C S | Procedimento per l'estrazione di esteri di acidi grassi poliinsaturi da olii di pesce e composizioni farmaceutiche e dietetiche contenenti detti esteri |
GB2218984B (en) * | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
GB8819110D0 (en) | 1988-08-11 | 1988-09-14 | Norsk Hydro As | Antihypertensive drug & method for production |
US5059622A (en) * | 1989-08-29 | 1991-10-22 | Biosyn, Inc. | Method for reducing blood pressure levels in hypertensive persons |
JP2893866B2 (ja) | 1990-05-25 | 1999-05-24 | 日本油脂株式会社 | 抗不整脈薬 |
US5324323A (en) | 1992-09-09 | 1994-06-28 | Telectronics Pacing Systems, Inc. | Multiple channel cardiosynchronous myoplasty apparatus |
US5208236A (en) | 1992-09-23 | 1993-05-04 | Schering Corporation | N-(acylaminomethyl)glutaryl amino acids and use |
US5683997A (en) | 1992-12-11 | 1997-11-04 | Ciba-Geigy Corporation | Substituted benzazepinones |
CN1082909A (zh) * | 1993-01-03 | 1994-03-02 | 潘玉珍 | 精制二十二碳六烯酸乙酯复合溶栓、抗痴呆药剂 |
JPH07118229A (ja) | 1993-10-19 | 1995-05-09 | Fujisawa Pharmaceut Co Ltd | 尿素誘導体およびその製造法 |
US5760081A (en) * | 1994-05-10 | 1998-06-02 | The General Hospital Corporation | Omega 3 fatty acids in the prevention of ventricular fibrillation |
JPH0812581A (ja) | 1994-06-30 | 1996-01-16 | Fujirebio Inc | 虚血性心疾患治療剤 |
IT1274734B (it) | 1994-08-25 | 1997-07-24 | Prospa Bv | Composizioni farmaceutiche contenenti acidi grassi poliinsaturi, loro esteri o sali, unitamente a vitamine o provitamine antiossidanti |
MY118354A (en) | 1995-05-01 | 2004-10-30 | Scarista Ltd | 1,3-propane diol derivatives as bioactive compounds |
IT1277953B1 (it) * | 1995-12-21 | 1997-11-12 | Sigma Tau Ind Farmaceuti | Composizione farmaceutica contenente l-carnitina o una alcanoil l- carnitina e un acido poliinsaturo della serie 3-omega utile per |
US6333447B1 (en) | 1996-03-29 | 2001-12-25 | The General Hospital Corporation | Transgenic model of heart failure |
US5861399A (en) | 1996-07-17 | 1999-01-19 | Heart Care Partners | Methods and compositions for the rapid and enduring relief of inadequate myocardial function |
JP2002514908A (ja) | 1996-09-05 | 2002-05-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | うっ血性心不全のための遺伝子治療 |
US6313167B1 (en) | 1997-06-16 | 2001-11-06 | Nippon Suisan Kaisha Ltd. | Composition having capability of removing risk factor during exercise |
IT1308613B1 (it) | 1999-02-17 | 2002-01-09 | Pharmacia & Upjohn Spa | Acidi grassi essenziali nella prevenzione di eventi cardiovascolari. |
EP1130027A1 (de) | 2000-02-29 | 2001-09-05 | Aventis Pharma Deutschland GmbH | Memno-Peptide, Verfahren zu ihrer Herstellung und Verwendung derselben |
-
1999
- 1999-02-17 IT IT1999MI000313A patent/IT1308613B1/it active
-
2000
- 2000-02-07 KR KR1020017010387A patent/KR100823051B1/ko active IP Right Review Request
- 2000-02-07 SK SK1080-2001A patent/SK286523B6/sk not_active IP Right Cessation
- 2000-02-07 JP JP2000599384A patent/JP5441287B2/ja not_active Expired - Lifetime
- 2000-02-07 HU HU0200111A patent/HUP0200111A3/hu unknown
- 2000-02-07 CA CA002362271A patent/CA2362271C/en not_active Expired - Lifetime
- 2000-02-07 CZ CZ20012947A patent/CZ301307B6/cs not_active IP Right Cessation
- 2000-02-07 EP EP20020076100 patent/EP1247523A1/en not_active Withdrawn
- 2000-02-07 DE DE60000133.4T patent/DE60000133C5/de not_active Expired - Lifetime
- 2000-02-07 EP EP00907510A patent/EP1152755B1/en not_active Expired - Lifetime
- 2000-02-07 AT AT00907510T patent/ATE216230T1/de active
- 2000-02-07 WO PCT/EP2000/000957 patent/WO2000048592A1/en not_active Application Discontinuation
- 2000-02-07 PT PT00907510T patent/PT1152755E/pt unknown
- 2000-02-07 ID IDW00200101999A patent/ID30205A/id unknown
- 2000-02-07 BR BR0008153-1A patent/BR0008153A/pt not_active Application Discontinuation
- 2000-02-07 AU AU29075/00A patent/AU775078B2/en not_active Expired
- 2000-02-07 EA EA200100895A patent/EA004312B1/ru not_active IP Right Cessation
- 2000-02-07 DK DK00907510T patent/DK1152755T3/da active
- 2000-02-07 ES ES00907510T patent/ES2174814T3/es not_active Expired - Lifetime
- 2000-02-07 NZ NZ513093A patent/NZ513093A/xx not_active IP Right Cessation
- 2000-02-07 US US09/869,333 patent/US7462643B1/en not_active Expired - Fee Related
- 2000-02-07 IL IL14437700A patent/IL144377A0/xx active IP Right Grant
- 2000-02-07 KR KR1020077019755A patent/KR20070098954A/ko not_active Application Discontinuation
- 2000-02-07 PL PL350851A patent/PL209078B1/pl unknown
- 2000-02-07 CN CNB008050732A patent/CN1230159C/zh not_active Expired - Lifetime
-
2001
- 2001-07-17 IL IL144377A patent/IL144377A/en not_active IP Right Cessation
- 2001-07-23 ZA ZA200106029A patent/ZA200106029B/en unknown
- 2001-08-14 NO NO20013938A patent/NO328797B1/no not_active IP Right Cessation
-
2002
- 2002-08-29 HK HK02106382.1A patent/HK1044720B/zh not_active IP Right Cessation
-
2008
- 2008-08-15 US US12/192,627 patent/US20090018193A1/en not_active Abandoned
-
2010
- 2010-01-07 JP JP2010014742A patent/JP2010116414A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5441287B2 (ja) | 心血管事象を予防するための必須脂肪酸 | |
MXPA05009432A (es) | Uso de acidos grasos omega-3 en el tratamiento de pacientes diabeticos. | |
JP2004517148A (ja) | 心機能不全および心不全の治療における必須n−3脂肪酸 | |
EP1474125A1 (en) | The use of omega-3 polyunsaturated acids ethyl esters in patients suffering from heart failure | |
KR20080024511A (ko) | 심혈관 이벤트 발병 예방용 조성물 | |
US20040235948A1 (en) | Treatment of diabetic patients with omega-3-fatty acids | |
JP2009544701A (ja) | オメガ3脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用 | |
AU2005244483B2 (en) | Essential fatty acids in the prevention and/or treatment of depression in patients with coronary heart or artery disease | |
JP2007532605A5 (ja) | ||
MXPA01008213A (en) | Essential fatty acids in the prevention of cardiovascular events | |
WO2005046668A1 (ja) | 言語障害予防・治療剤 | |
WO1993009773A1 (en) | Preventive or curative for dysmenorrhea and food having function of preventing dysmenorrhea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051005 |
|
A625 | Written request for application examination (by other person) |
Free format text: JAPANESE INTERMEDIATE CODE: A625 Effective date: 20051005 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090707 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090930 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091007 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20100112 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100112 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100330 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20100519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100729 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20100729 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20101007 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20101112 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20110131 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20110131 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20111129 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120203 |
|
RD13 | Notification of appointment of power of sub attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7433 Effective date: 20120203 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120203 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120305 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120312 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120330 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120406 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130705 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130807 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131217 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 Ref document number: 5441287 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |